Yokkaichi, Japan

Ikuo Matsukuma


Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 90(Granted Patents)


Location History:

  • Machida, JP (1979 - 1980)
  • Susono, JP (1986)
  • Yokkaichi, JP (1981 - 1988)
  • Tokyo, JP (1989 - 1992)

Company Filing History:


Years Active: 1979-1992

Loading Chart...
12 patents (USPTO):Explore Patents

Title: Ikuo Matsukuma: Innovator in Anti-Tumor Compounds

Introduction

Ikuo Matsukuma is a notable inventor based in Yokkaichi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor compounds. With a total of 12 patents to his name, Matsukuma's work has had a profound impact on cancer treatment.

Latest Patents

Matsukuma's latest patents include innovative compounds such as 6H-pyrazolo-[4,5,1-d,e]acridin-6-one derivatives, which exhibit excellent anti-tumor activity. These novel pyrazoloacridone compounds, along with their pharmaceutically acceptable salts, have shown promising results in combating tumors. Additionally, he has developed mitomycin derivatives that possess potent anti-tumor activity against solid sarcoma 180 tumors and lymphocytic leukemia P-388 tumors.

Career Highlights

Throughout his career, Matsukuma has worked with prominent companies in the pharmaceutical industry, including Kyowa Hakko Kogyo Co., Ltd. and Kyowa Hakko Kogyo K.K. His dedication to research and innovation has led to advancements in cancer therapies, making him a respected figure in his field.

Collaborations

Matsukuma has collaborated with esteemed colleagues such as Tadashi Hirata and Yukio Hashimoto. These partnerships have contributed to the success of his research and the development of effective anti-tumor agents.

Conclusion

Ikuo Matsukuma's contributions to the field of anti-tumor compounds highlight his innovative spirit and commitment to improving cancer treatment. His patents and collaborations reflect a career dedicated to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…